CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Gabapentin, Phenobarbital, Diazepam, and Lorazepam for the Treatment of Alcohol Withdrawal: Clinical Effectiveness and Guidelines

Last updated: June 24, 2020
Project Number: RB1498-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of gabapentin, phenobarbital, diazepam, and lorazepam for the management of individuals with alcohol withdrawal?
  2. What are the evidence-based guidelines regarding the management of individuals with alcohol withdrawal in the emergency department?
  3. What are the evidence-based guidelines regarding the provision of addiction services to vulnerable populations with alcohol withdrawal during the coronavirus pandemic?

Key Message

Two systematic reviews and eleven non-randomized studies were identified regarding the clinical effectiveness of gabapentin, phenobarbital, diazepam, and lorazepam for the management of individuals with alcohol withdrawal. Four evidence-based guidelines were identified regarding the management of individuals with alcohol withdrawal in the emergency department. No relevant evidence-based guidelines were identified regarding the provision of addiction services to vulnerable populations with alcohol withdrawal during the coronavirus pandemic.